Jenny Harry, CEO of Proteome Systems, said: “Over the past few years, the management team has focused on leveraging the company’s core strengths in the validation and development of biomarkers and diagnostic tests.
“The divestiture of the technology platform and an exit from the therapeutic business enabled the allocation of the appropriate resources to achieve corporate growth. This fundamental shift in strategy has prompted the name change, and we are pleased to have the support of our shareholders.”